LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population

Vekić, Jelena; Topić, Aleksandra; Jelić‐Ivanović, Zorana; Spasojević‐Kalimanovska, Vesna

doi:10.1016/j.clinbiochem.2006.11.013

Cited by 58 publications

(52 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study was performed on patients who we re sent to the Dispensary for Atherosclerosis Pre vention, Centre for Laboratory Medicine, Clinical Centre of Vojvo dina, mainly for the lipid metabolism disorder treatment, therefore the mean values of lipid pa ra meters except HDL cholesterol are higher in our subjects in comparison to other similar studies (17)(18)(19).…”

Section: Frs Frs Atp Frs W Prs Prs Ns Prs Ch Score Lr Ir Hr Lr Ir Hr contrasting

confidence: 39%

See 1 more Smart Citation

Evaluation of Coronary Risk Score Applications in 10-Year Coronary Heart Risk Estimation

Eremić¹,

Đerić²

2009

Journal of Medical Biochemistry

View full text Add to dashboard Cite

identifikacije i le~enja asimp tomatskih osoba s visokim rizikom za razvoj koronarne bolesti srca (KBS) u praksi se koriste razli~iti bodovni sistemi za procenu rizika. Cilj ovog istra`ivanja je da se izvr{i upore|ivanje SCORE bodovnog sistema preporu~enog za na{u sredinu sa ostala dva naj~e{}e kori{}ena bodovna sistema za pro ce nu 10-godi{njeg rizika za KBS: Framinghamskog i PROCAM sistema, kao i njihovih modifikacija. Od 220 pregledanih ispitanika oba pola, upu}enih u Ambulantu za pre venciju ateroskleroze Klini~kog centra Vojvodine prvenstveno radi le~enja lipidskog poreme}aja, 110 je uklju~eno u na{u studiju i pra}eno godinu dana. Prilikom prvog pregleda, osoba s niskim rizikom je bilo od 15% prema skoru Framingham Weibull do 78% prema skoru PRO -CAM, srednjim od 12% prema PROCAM NS do 45% prema Framingham Weibullu, a visokim od 8% prema PRO -CAM-u do 40% prema Framigham Weibullu. Posle godinu dana le~enja, u kategoriji niskog rizika bilo je od 30% prema Framingham Weibullu do 88% prema PROCAM-u, srednjeg od 10% prema PROCAM-u do 36% prema Framingham Weibullu, a visokog od 2% pre ma PROCAM-u do 25% prema Framingham Weibullu. Kako su lipidski pa rametri zna~ajni kriterijumi svih bodovnih siste ma za pr ocenu rizika od KBS, ustanovljeno je o~ekivano signifi kan tno sni `enje broja ispitanika u kategoriji visokog, a po ve }anje u kategoriji niskog rizika posle godinu dana le ~enja lipidskog poreme}aja, procenjivano prema svim ispi tivanim bodovnim sistemima.Klju~ne re~i: koronarna bolest srca, faktori rizika, pro cena rizika, hiperlipidemija Summary: Atherosclerosis is a multifactorial disease with risk factors that have multiple effects. In the identification and treatment of asymptomatic indi viduals at high risk for developing coronary heart disease (CHD) diffe rent risk scoring schemes are used in everyday routine. The aim of this study was to compare SCORE recommended for our country with two other most frequently used risk schemes for 10-year CHD risk evaluation: Framingham and PROCAM as well as their modifications. From 220 examined subjects of both sexes, who were treated mainly for lipid metabolism disorder at the Dispensary for Atherosclerosis Prevention, Centre for Labor atory Medicine, Clinical Centre of Vojvodina, 110 subjects were included in our study and agreed to a one-year follow-up. At first check-up, 15% had low risk according to Framin gham Weibull and 78% according to PROCAM, intermediate 12% according to PROCAM NS up

show abstract

Section: Frs Frs Atp Frs W Prs Prs Ns Prs Ch Score Lr Ir Hr Lr Ir Hr contrasting

confidence: 39%

“…In three studies, Veki} et al (18), Jovi~i} et al (19) and Cristobala et al (17) the mean values of systolic and diastolic blood pressure were similar to values in our subjects. There were no significant differences between gender in our study and the three other compared studies.…”

Section: Frs Frs Atp Frs W Prs Prs Ns Prs Ch Score Lr Ir Hr Lr Ir Hr mentioning

confidence: 91%

Evaluation of Coronary Risk Score Applications in 10-Year Coronary Heart Risk Estimation

Eremić¹,

Đerić²

2009

Journal of Medical Biochemistry

View full text Add to dashboard Cite

show abstract

“…A detailed description of the procedure has been published elsewhere 23,24) . Based on the dominant diameter, we classified the LDL phenotype as phenotype A (＞25.5 nm) or phenotype B (≤ 25.5 nm).…”

Section: Ldl and Hdl Subclass Determinationmentioning

confidence: 99%

Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients

Mirjanic-Azaric

Vekić

Zeljković

et al. 2014

JAT

Self Cite

View full text Add to dashboard Cite

Aim:We hypothesized that, in stable angina patients, atorvastatin therapy lowers the cathepsin S (CTSS) concentrations, as assessed non-invasively according to a plasma analysis. In addition, the low-density lipoprotein (LDL) and high-density lipoprotein (HDL) size and subclasses in the plasma were analysed to establish the association between CTSS and lipoprotein metabolism and determine whether this association is atorvastatin-sensitive. Methods: A total of 43 patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). The plasma CTSS mRNA levels, CTSS protein concentrations and CTSS activity, as well as LDL and HDL size and subclasses, were analysed before and after treatment. Results: Atorvastatin treatment did not change the plasma CTSS mRNA levels, although it lowered the plasma CTSS concentrations and activity. An increased plasma CTSS concentration and activity were found to be associated with a more atherogenic LDL subclass profile (a decreased dominant LDL size and increased percentage of small, dense LDL particles). The atorvastatin-induced CTSSlowering effect was concomitant with an improvement in the LDL subclass profile, and the changes were found to be interrelated. Concomitant, interrelated changes in the CTSS levels and LDL subclass profiles were found in the LDL phenotype B patients only (a dominant LDL diameter of ≤ 25.5 nm at the start of the study). In this subgroup, lowering of the plasma CTSS mRNA level also correlated with lowering of the proportion of small, dense LDL particles. Conclusions: Atorvastatin-induced CTSS-lowering and LDL subclass profile improvements in the plasma of LDL phenotype B patients with stable angina are concomitant and interrelated. J Atheroscler Thromb, 2014; 21:868-877.

show abstract

“…The size for LDL of 25.5 nm or less and HDL of 8.8 nm or less were the criteria used for the definition of smaller, denser LDL and HDL particles (i.e., LDL B and HDL 3 phenotypes). 19 The relative content of each LDL and HDL subclass was estimated by determining the areas under the peaks of densitometric scans of plasma samples stained with Sudan black.…”

Section: Low-density Lipoprotein and Hdl Subclass Determinationmentioning

confidence: 99%

“…19 In brief, electrophoresis was performed at 88C in a Hoefer SE 600 Ruby electrophoresis unit (Amersham Pharmacia Biotech, Vienna, Austria) with TrisÀboric acidÀdisodium EDTA buffer, pH 8.35 for 20 hours. Gels were calibrated by using the Pharmacia highmolecular weight protein standards, carboxylated polystyrene microsphere beads, and human plasma with 2 LDL subclasses.…”

Section: Low-density Lipoprotein and Hdl Subclass Determinationmentioning

confidence: 99%

Distribution of Low-Density Lipoprotein and High-Density Lipoprotein Subclasses in Patients With Sarcoidosis

Vekić

Zeljković

Jelić‐Ivanović

et al. 2013

Archives of Pathology &Amp; Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Context.-Systemic inflammatory diseases are associated with proatherogenic lipoprotein profile, but there is a lack of information regarding overall distributions of lipoprotein subclasses in sarcoidosis.Objective.-To investigate whether patients with sarcoidosis have altered distributions of plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles.Design.-Seventy-seven patients with biopsy-proven sarcoidosis (29 with acute and 48 with chronic sarcoidosis) treated with corticosteroids and 77 age-and sex-matched controls were included in the study. Low-density lipoprotein and HDL subclasses were determined by gradient gel electrophoresis, while inflammatory markers and lipid parameters were measured by standard laboratory methods.Results.-Compared to controls, patients had fewer LDL I subclasses (P , .001), but more LDL II and III (P , .001) subclasses. This pattern was evident in both acute and chronic disease groups. Patients also had smaller HDL size (P , .001) and higher proportions of HDL 2a (P ¼ .006) and 3a particles (P ¼ .004). Patients with chronic sarcoidosis had smaller LDL size than those with acute disease (P ¼ .02) and higher proportions of HDL 3a subclasses (P ¼ .04) than controls. In acute sarcoidosis, relative proportions of LDL and HDL particles were associated with levels of inflammatory markers, whereas in chronic disease an association with concentrations of serum lipid parameters was found.Conclusions.-The obtained results demonstrate adverse lipoprotein subfraction profile in sarcoidosis with sustained alterations during disease course. Evaluation of LDL and HDL particles may be helpful in identifying patients with higher cardiovascular risk, at least for prolonged corticosteroid therapy due to chronic disease course.

show abstract

LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population

Cited by 58 publications

References 34 publications

Evaluation of Coronary Risk Score Applications in 10-Year Coronary Heart Risk Estimation

Evaluation of Coronary Risk Score Applications in 10-Year Coronary Heart Risk Estimation

Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients

Distribution of Low-Density Lipoprotein and High-Density Lipoprotein Subclasses in Patients With Sarcoidosis

Contact Info

Product

Resources

About